Brought to you by 
Series D raises $60mm for Biolex to support Locteron trials
09 Oct 2008
Executive Summary
Protein and antibody developer Biolex Therapeutics raised $60mm in its Series D financing led by new investor Clarus Ventures. First-time backer OrbiMed Advisors was joined by returning shareholders Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corp., Investor Growth Capital, Polaris Ventures, Mitsui & Co. Ltd., Dow Chemical Co., JP Morgan Securities, and the North Carolina Economic Development Fund. Biolex will use the money to complete Phase II and prepare for Phase III trials of Locteron, to which the company recently received full rights from co-development partner OctoPlus. Representatives from Clarus and OrbiMed will take seats on Biolex's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D raises $60mm for Biolex to support Locteron trials
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice